Tyra Biosciences, Inc.

Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. TYRA’s in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help TYRA design and predict which candidates may demonstrate the highest potency, selectivity and tolerability in the clinic. TYRA’s expertise in FGFR biology has created a differentiated pipeline with clinical-stage programs in targeted oncology and genetically defined conditions. TYRA’s lead precision candidate stemming from SNÅP, oral dabogratinib, is a potential first-in-class selective FGFR3 inhibitor in development for LG UTUC, IR NMIBC and ACH. TYRA is also developing TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4- driven cancers, in the SURF431 study for advanced hepatocellular carcinoma, and TYRA-200, an oral, investigational FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma. TYRA is based in Carlsbad, California.

Current securities

1. 4 filingSep 17, 2026
2. 4 filingSep 17, 2026
3. SCHEDULE 13D/A - filed by RA CAPITAL MANAGEMENT, L.P. regarding Tyra Biosciences, Inc.Sep 17, 2026
4. 4 filingSep 17, 2026
5. SCHEDULE 13G - filed by Paradigm Biocapital Advisors LP regarding Tyra Biosciences, Inc.Sep 17, 2026